NEW HAVEN, Conn., March 20 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc., (NASDAQ:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overview and update on the Company's clinical programs in HIV, HCV and serious bacterial infections at the 2007 Future Leaders in the Biotech Industry Conference, hosted by BioCentury and Thomson Financial. The Company presentation will take place on Thursday, March 29, 2007 from 2:00-2:25pm.
To access the live audio broadcast and the subsequent archived audio recording of the Company presentation, please log onto the Company's website www.achillion.com under the "Investors" section. The audio recording will be archived there for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. Achillion is currently developing treatments for HIV infection, chronic hepatitis C infection and serious hospital-based bacterial infections. For more information on Achillion Pharmaceuticals, please visit the company's web site at www.achillion.com or call Achillion at 1-203-624-7000. ACHN-G
Contact: Media: Mary Kay Fenton Kari Watson Achillion Pharmaceuticals, Inc. MacDougall Biomedical Communications Tel. (203) 624-7000 Tel. (508) 647-0209 firstname.lastname@example.org email@example.com
Source: Achillion Pharmaceuticals, Inc.